Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option

REDWOOD CITY, Calif., July. 24 (Korea Bizwire) – Rezolute, Inc. (“Rezolute”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of transformative therapies targeting metabolic and orphan diseases, announced today that Handok, Inc. (“Handok”) and Genexine, Inc. (“Genexine”), exercised their combined full $20 million option to purchase shares of Rezolute common stock, increasing their combined aggregate investment [...]